探究喹诺酮类药物治疗结核病患者的临床价值及安全性
|
摘要
目的:探究喹诺酮类药物治疗结核病患者的临床价值及安全性。方法:在2015年6月至2017年8月,选取我院结核病患者200例,均分为对照组与观察组,对照组给予常规抗核药物治疗,观察组给予常规抗核药物及喹诺酮类药物治疗,观察患者临床效果、不良反应发生率。结果:观察组患者临床效果比对照组好,P<0.05,不良反应发生率与对照组相比,差异较小,P>0.05。结论:给予结核病患者喹诺酮类药物治疗,能提高临床效果,不良反应少,安全性高,值得借鉴。
Objective: To explore the clinical value and safety of quinolones in the treatment of tuberculosis patients. Methods:from June 2014 to August 2017,our hospital 200 cases of patients with tuberculosis,were divided into control group and observation group,control group given conventional antinuclear drug therapy,the observation group was given conventional nuclear drugs and quinolones treatment,the clinical effect,the incidence of adverse reactions were observed. Results: the clinical effect of the patients in the observation group was better than that of the control group,P< 0.05,and the incidence of adverse reactions was smaller than that of the control group,P> 0.05. Conclusion: the treatment with quinolones in patients with tuberculosis can improve the clinical effect with less adverse reactions and high safety.
Objective: To explore the clinical value and safety of quinolones in the treatment of tuberculosis patients. Methods:from June 2014 to August 2017,our hospital 200 cases of patients with tuberculosis,were divided into control group and observation group,control group given conventional antinuclear drug therapy,the observation group was given conventional nuclear drugs and quinolones treatment,the clinical effect,the incidence of adverse reactions were observed. Results: the clinical effect of the patients in the observation group was better than that of the control group,P< 0.05,and the incidence of adverse reactions was smaller than that of the control group,P> 0.05. Conclusion: the treatment with quinolones in patients with tuberculosis can improve the clinical effect with less adverse reactions and high safety.
引文
[1]李哲明,谭守勇,邝浩斌,等.早期广泛耐药肺结核近期临床疗效分析[J].实用医学杂志,2016,32(11):1764-1766.
[2]沙巍,张青,崔文玉,等.首次复治肺结核患者短程化疗新方案的临床研究[J].中国防痨杂志,2017,39(1):39-45.
[3]杜鹃,田丹,陈国玺,等.初治涂阳肺结核患者采用含氟喹诺酮类药物治疗方案的疗效分析[J].中国防痨杂志,2016,38(11):968-972.
[4]宗兆婧,荆玮,霍凤敏,等.84株广泛耐药结核分枝杆菌对新型氟喹诺酮类药物的耐药情况分析[J].中国防痨杂志,2017,39(8):809-814.
[5]崔振玲,陆俊梅,杨华,等.复治肺结核患者对氟喹诺酮类药物交叉耐药情况的体外研究[J].中国防痨杂志,2017,39(1):51-56.
[6]淳于柳爽,王东晓,管希周,等.1例未成年结核性胸膜炎患者使用喹诺酮类药物的药学监护[J].中国药物应用与监测,2017,14(1):27-30.
[2]沙巍,张青,崔文玉,等.首次复治肺结核患者短程化疗新方案的临床研究[J].中国防痨杂志,2017,39(1):39-45.
[3]杜鹃,田丹,陈国玺,等.初治涂阳肺结核患者采用含氟喹诺酮类药物治疗方案的疗效分析[J].中国防痨杂志,2016,38(11):968-972.
[4]宗兆婧,荆玮,霍凤敏,等.84株广泛耐药结核分枝杆菌对新型氟喹诺酮类药物的耐药情况分析[J].中国防痨杂志,2017,39(8):809-814.
[5]崔振玲,陆俊梅,杨华,等.复治肺结核患者对氟喹诺酮类药物交叉耐药情况的体外研究[J].中国防痨杂志,2017,39(1):51-56.
[6]淳于柳爽,王东晓,管希周,等.1例未成年结核性胸膜炎患者使用喹诺酮类药物的药学监护[J].中国药物应用与监测,2017,14(1):27-30.